sdü tıp fak derg Medical Journal of Süleyman Demirel University 2602-2109 Süleyman Demirel Üniversitesi CASTLEMAN HASTALIĞI: İKİ OLGU SUNUMU VE LİTERATÜRÜN GÖZDEN GEÇİRİLMESİ Yıldız Mustafa Yıldırım Mustafa Parlak Cem Bülbüller Nurullah Eryılmaz Ramazan Sezer Cem Yaz Müjgan Süren Dinç Kaya Çetin 12 30 2012 19 4 151 155 08 25 2010 Copyright © 1994, Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi 1994 Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Castleman hastalığı (CH) anjiofoliküler displazi olarak da adlandırılan lenfoproliferatif bir hastalıktır. Multisentrik ve unisentrik olmak üzere farklı prognozlara sahip iki farklı hastalığı içermektedir.CH lenf nodunun yapısını koruyarak büyümesi ile karakterize bir hastalıktır. Hyalin vasküler, plazma hücreli ve mikst tip olmak üzere üç temel varyant tanımlanmıştır.CH'nin patogenezine yönelik çalışmalar daha çok multisentrik CH (MCH) HHV 8 (+) hastalığa yönelik yapılmıştır. Unisentrik CH (UCH) ve HHV8 (-) MCH' lı hastalarda patogenez net değildir. CH malign seyirli lezyonlarla karışabilmektedir. Bu yazıda biri unisentrik hyalin vasküler varyant ve diğeri multisentrik plazma hücreli varyantlı iki olgumuz güncel literatür ışığında tartışılmıştır.

 Castleman hastalýðý Olgu sunumu Literatür derlemesi Castleman, B, Iverson, L, Menedez, VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956; 9:822 Gaba, AR, Stein, RS, Sweet, DL, Variakojis, D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978; 69:86. Frizzera, G. Atypical lymphoproliferative disorders. In: Neoplastic Hematopathology, Knowles, DM (Ed), Lippincott, Williams and Wilkins, Philadelphia 2001. p.595. Keller, AR, Hochholzer, L, Castleman, B. Hyaline- vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972; 29:670. Dupin, N, Diss, TL, Kellam, P, et al. HHV-8 is associated with a plasmablastic variant of CD that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000; 95:1406. Y. Dong, J. NA et all. Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a singlecenter. Leukemia&Lymphoma, August 2009;50(8):1308–1317 Peterson, BA, Frizzera, G. Multicentric CD. Semin Oncol 1993; 20:636 Chang, Y, Cesarman, E, Pessin, MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865. Gessain, A, Briere, J, Angelin-Duclos, C, et al. Human herpes virus 8 ( 25.Kaposi's sarcoma herpes virus) and malignant lymphoproliferations in France: A molecular study of 250 cases including two AIDS-associated body cavity based lymphomas. Leukemia 1997; 11:266. Soulier, J, Grollet, L, Oksenhendler, E, et al. Kaposi's Sarcoma-associated herpesvirus-like DNA sequences in multicentric CD. Blood 1995; 86:1276. Yoshizaki, K, Matsuda, T, Nishimoto, N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in CD. Blood 1989; 74:1360. Leger-Ravet, MB, Peuchmaur, M, Devergne, O, et al. Interleukin-6 gene expression in CD. Blood 1991; 78:2923. Aoki, Y, Jaffe, ES, Chang, Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999; 93:4034. An, J, Lichtenstein, AK, Brent, G, Rettig, MB. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood 2002; 99:649. Oksenhendler, E, Carcelain, G, Aoki, Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000; 96:2069. Chih-HaoChen, Hung-Chang Liu et all. Possible roles of Epstein-Barr virus in Castleman disease Journal of Cardiothoracic Surgery 2009 4:31 Murray PG, Deacon E, et all. Localization of Epstein- Barr virus in Castleman's disease by in situ hybridization and immunohistochemistry. Hematol Pathol 1995,9:17- 26 Bowne, WB, Lewis, JJ, Filippa, DA, et al. The management of unicentric and multicentric CD: A report of 16 cases and a review of the literature. Cancer 1999; 85:706. Chronowski, GM, Ha, CS, Wilder, RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92:670. Estephan, FF, Elghetany, MT, Berry, M, Jones, DV Jr. Complete remission with anti-CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman's disease. Cancer Invest 2005; 23:191 deVries et all. Neoadjuvant radiotherapy of primary irresectable unicentric Castleman’s disease: a case report and review of theliterature Radiation Oncology 2010, 5:7 Maslovsky, I, Uriev, L, Lugassy, G. The heterogeneity of Castleman disease: Report of five cases and review of the literature. Am J Med Sci 2000; 320:292. Frizzera, G, Peterson, BA, Bayrd, ED, Goldman, A. A systemic lymphoproliferative disorder with morphologic features of CD: Clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985; 3:1202. Weisenburger, DD, Nathwani, BN, Winberg, CD, Rappaport, H. Multicentric angiofollicular lymph node hyperplasia: A clinicopathologic study of 16 cases. Hum Pathol 1985; 16:162. Zietz, C, Bogner, JR, et al. An unusual cluster of cases of CD during highly active antiretroviral therapy for AIDS. N Engl J Med 1999; 340:1923. Casper, C, Nichols, WG, Huang, ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103:1632. Nishimoto, N, Sasai, M, Shima, Y, et al. Improvement in CD by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95:56. Matsuyama M, Suzuki T, Tsuboi H, et al. Anti- interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease. Intern Med. 2007;46:771-4 Gerard, L, Berezne, A, Galicier, L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007; 25:3350. Lee, FC, Merchant, SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003; 73:48. Starkey, CR, Joste, NE, Lee, FC. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am JHematol 2006; 81:303.